Although the patients in our study were less heavily pretreated than patients in the studies of KarMMa and CARTITUDE-1 due to the limited availability of innovative drugs, especially CD38 monoclonal antibody in China, BC19 CAR T cells exhibited a promising responsive rate, depth, and durability in patients with R/R MM. The gene discussed is CD38; the disease is Miyoshi myopathy.